- Home
- JKHY vs RVMD Comparison
JKHY vs RVMD Comparison
Compare JKHY & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKHY | RVMD |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 15.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | JKHY | RVMD |
|---|---|---|
| Price | $178.33 | $78.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 17 |
| Target Price | ★ $185.60 | $77.47 |
| AVG Volume (30 Days) | 777.3K | ★ 2.3M |
| Earning Date | 02-03-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ 20.28 | N/A |
| EPS | ★ 6.58 | N/A |
| Revenue | ★ $2,419,044,000.00 | N/A |
| Revenue This Year | $7.52 | N/A |
| Revenue Next Year | $6.26 | $714.50 |
| P/E Ratio | $27.11 | ★ N/A |
| Revenue Growth | ★ 7.75 | N/A |
| 52 Week Low | $144.12 | $29.17 |
| 52 Week High | $196.00 | $81.97 |
Technical Indicators
Market Signals| Indicator | JKHY | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 59.23 |
| Support Level | $184.65 | $78.97 |
| Resistance Level | $186.90 | $81.97 |
| Average True Range (ATR) | 2.87 | 2.25 |
| MACD | -1.48 | -0.62 |
| Stochastic Oscillator | 8.26 | 65.61 |
Price Performance
Historical ComparisonAbout JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.